Nivolumab plus ipilimumab improved long-term survival in patients with advanced melanoma
1. The 6.5-year progression-free survival for the nivolumab combination group, nivolumab group and in the ipilimumab group were 34%, 29% ...
Tag: anti-PD-L1 resistant melanoma
#VisualAbstract: Ipilimumab plus anti-PD-1 therapy is effective in patients with anti-PD-L1 resistant metastatic melanoma
Click to read the study in The Lancet Oncology.